Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Announces CEO Transition
Steven Lo appointed President and CEO; John Walker remains as Chairman of the Board   FREMONT, Calif. , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Steven Lo, veteran biotechnology and pharmaceutical
View HTML
Toggle Summary Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FREMONT, Calif. , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 100,000 shares of Zosano’s common stock to a new employee as an inducement award.
View HTML
Toggle Summary Zosano Pharma to Present at the Cantor Global Healthcare Conference
FREMONT, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker , will present a company overview at the 2019 Cantor Global Healthcare
View HTML
Toggle Summary Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business Development
FREMONT, Calif. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Dushyant Pathak , Ph.D., as senior vice president of business development. “We are pleased to welcome Dushyant, who brings
View HTML
Toggle Summary Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache Society
- Repeated Dosing of Qtrypta Over the Course of One Year Reaffirms Qtrypta is Effective and Well-Tolerated as an Acute Treatment for Migraine - - Efficacy and Safety Profile Consistent in Sub Analyses of Patients Taking Concurrent Medications- -Company is Preparing for a New Drug Application (NDA)
View HTML
Toggle Summary Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference
FREMONT, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker , will present a company overview at the H.C.
View HTML
Toggle Summary Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society
Oral presentation of the safety and efficacy of Qtrypta TM in a long-term safety study for the acute treatment of migraine. Poster on the results of patients’ freedom from pain and most bothersome symptom when taking Qtrypta concurrently with prophylactic anti-CGRP antibodies.
View HTML
Toggle Summary Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 1:30 p.m. PT today FREMONT, Calif. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2019 , as well as recent business
View HTML
Toggle Summary Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster Headache
FREMONT, Calif. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) to initiate a Phase
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on Second Quarter 2019 Financial Results and Provide Operational Update
FREMONT, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, August 14, 2019 at 4:30 p.m. ET to discuss results for the second quarter of 2019
View HTML